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Prion diseases are presumed to be caused by the accumulation in the brain of a pathological protein
called prion protein (PrP) scrapie which results from the transconformation of cellular PrP, a ubiquitous
glycoprotein expressed in all mammals. Since all isoforms of PrP are perceived as self by the host
immune system, a major problem in designing efficient immunoprophylaxis or immunotherapy is to
overcome tolerance. The present study was aimed at investigating whether bone-marrow-derived
dendritic cells (DCs) loaded with peptides previously shown to be immunogenic in PrP-deficient mice,
can overcome tolerance in PrP-proficient wild-type mice and protect them against scrapie. Results
show that, in such mice, peptide-loaded DCs elicit both lymphokine release by T cells and antibody
secretion against native cellular PrP. Repeated recalls with peptide-loaded DCs reduces the attack
rate of 139A scrapie inoculated intraperitoneally and retards disease duration by 40 days. Most
interestingly, survival time in individual mice appears to be correlated with the level of circulating
antibody against native cellular PrP.
INTRODUCTION
Prion diseases, also called transmissible spongiform
encephalopathies (TSEs), are fatal neurodegenerative dis-
orders which progress slowly, induce severe neurological
loss and are transmissible. The agent is most presumably
the scrapie prion protein (PrP) or PrPSc, a misfolded
protein, rich in beta-sheets, resulting from the transcon-
formation of cellular PrP (PrPc). PrPc is a ubiquitous,
membrane-anchored protein, which has been remarkably
conserved through evolution, but whose function in health
is still enigmatic. The presence of PrPSc in tissues of
diseased individuals confirms the diagnosis TSE (Prusiner
et al., 1998; Wisniewski et al., 1998).
Prions do not spontaneously evoke antibody (Ab) or T-cell
responses in diseased subjects, most likely because PrPSc,
like PrPc, is not perceived as foreign or ‘dangerous’
(Matzinger, 1998) by the host immune system. In recent
years, however, following encouraging immunotherapy
results in Alzheimer’s disease patients (Schenk et al., 1999),
several teams have attempted to passively or actively
generate adaptive immune responses against prions in
wild-type (wt) mice and have shown that passive Ab
treatment (Sigurdsson et al., 2003; White et al., 2003),
constitutive transgenic secretion of anti-PrP IgM (Heppner
et al., 2001) or active immunization using whole PrP
(Sigurdsson et al., 2002), PrP peptides (Schwarz et al.,
2003), PrP fragments (Bade et al., 2006) or DNA constructs
encoding Prnp gene sequences (Fernandez-Borges et al.,
2006) had beneficial effects on disease evolution.
In order to identify major histocompatibility (MHC) class
II-restricted T-cell epitopes in C57BL6 (B6)–H-2b mice, we
previously screened a bank of overlapping peptides of
mouse PrP and identified two main epitopes. One is
contained in peptide PrP97–128, the other is shared by
peptides PrP143–172 and PrP158–187. Immunization of mice
made genetically deficient for PrP (Prnp2/2) with PrP97–128
induces moderate T-cell responses but good Ab secretion,
including Abs to native, cell-bound PrPc, whereas PrP158–
187 elicits strong cellular responses but few Abs to the native
protein (Gregoire et al., 2004). When injected into wt mice,
the same peptides trigger no response unless they are
administered together with a potent adjuvant such as CpG-
ODN (Rosset et al., 2004). Furthermore, the Abs generated
under such conditions bind to plastic-immobilized recom-
binant PrP, but not to cell-surface native PrPc, suggesting
that B cells which recognize native PrPc with good affinity
are deleted during ontogeny (Gregoire et al., 2005;
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Polymenidou et al., 2004). Given the current assumption
that immune protection against TSEs is primarily effected
by Ab specific for cell-bound PrP, a major objective is to
develop vaccines which will generate Abs of such specificity
in wt mice. Nikles et al. (2005) have obtained promising
results by using retroviral particles which display the C-
terminal 111 aa of PrP (Nikles et al., 2005). We propose
here an alternative strategy based on vaccination with
syngeneic dendritic cells (DCs) loaded with the previously
identified immunogenic PrP peptides. Here, we show
firstly that pulsed DCs can successfully elicit T- and B-cell-
responses against PrPc in wt mice and secondly, that
repeated DC recalls delay scrapie progression in peripher-
ally infected mice.
RESULTS
PrP-expressing DCs elicit anti-PrP immune
responses in Prnp”/” mice
Before probing DCs in wt mice, we verified that they could
raise anti-PrP T- and B-cell-responses in non-tolerant
Prnp2/2 mice. Four female mice were immunized twice
intraperitoneally (i.p.) at 15 day intervals with 16106 DCs
differentiated from wt bone-marrow (BM) B6 precursors
and thus expressing PrPc (PrP+ DCs). Control mice
received PrP2 DCs differentiated from Prnp2/2 BM
donors. Spleen T cells and sera were collected 10 days
after the second challenge. As shown in Fig. 1(a), T cells
from all four mice injected with PrP+ DCs secreted gamma
interferon (IFN-c) upon in vitro challenge with antigen-
presenting cells (APCs)+PrP158–187. In mice that had
received PrP2 DCs or PBS, secretion was at background
levels. The number of spots increased with the in vitro
concentration of peptide, confirming that cytokine release
depended on specific antigen recognition (Fig. 1b).
Next, we looked for Abs against cell-bound PrPc. A typical
overlay (Fig. 1c) shows EL4 cells with secondary Ab only,
cells incubated with a normal mouse serum plus secondary
Ab and cells incubated with a serum from a DC-vaccinated
mouse plus secondary Ab. We checked that the Abs present
in serum were also staining PrP+ splenocytes from wt mice
and not PrP2 splenocytes from Prnp2/2 mice (data not
shown). As Fig. 1(d) shows, the sera from the four Prnp2/2
mice immunized with PrP+ DCs produced mean fluor-
escent intensity (MFI) values well above those of sera from
mice injected with PrP2 DCs or PBS. Differences were
significant between the three groups by Kruskal–Wallis test
(P,0.05) and by Dunn’s two by two between PrP+ DCs
and PBS (P,0.01).
Overcoming tolerance in wt mice requires
peptide-loaded DCs
To elicit responses in wt mice, we injected either unloaded
PrP+ DCs or PrP+ DCs loaded with PrP98–127 or PrP158–187.
Viable DCs (16106) were administered at 15 day intervals
and spleen T cells and sera were collected 10 days after the
last challenge. Fig. 2(a) shows that only mice injected with
DCs loaded with PrP158–187 mounted a substantial IFN-c
Fig. 1. PrP+ DCs elicit T- and B-cell
responses in non-tolerant Prnp”/” mice. Mice
were injected i.p. twice at a 15 day interval with
1106 unloaded DCs differentiated from wt
PrP+ or Prnp”/” BM. A third group received
PBS. (a) Each point represents the frequency
of IFN-c spots per 1106 T cells from
individual mice probed with 15 mg ml”1
PrP158–187. The short horizontal line shows
the median. (b) Spot frequency increases with
the concentration of peptide PrP158–187
present in the ELISPOT assay. Each column
shows the mean number of spots±SD of
triplicate cultures. (c) Typical overlay of acti-
vated EL4 cells incubated with the secondary
Ab only (shaded), incubated with a normal
mouse serum and secondary Ab (thin black
line) or with an immune serum (1 : 20 dilution)
and secondary (thick grey line). (d) MFI values
(shown at 1 : 20 serum dilution) of mice
immunized with PrP+ DCs, PrP” DCs or
PBS. Short horizontal lines show the geomet-
ric means.
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response, with a median spot frequency around 200. In
contrast, few spots were generated in mice injected with DCs
plus PrP98–127 and even less were generated in mice that had
received unloaded PrP+ DCs. Contrasting with their
poor IFN-c responses, mice immunized with DCs plus
PrP98–127 mounted good interleukin (IL)-4 responses
(Fig. 2b), the differences were not significant by the
Mann–Whitney test, from mice that had received DCs
loaded with PrP158–187. Mice that had been injected with
unloaded DCs remained unresponsive. In summary,
T cells of wt B6 mice responded only to peptide-loaded
DCs. Loading with PrP158–187 elicits a double response of
IFN-c and IL-4, while loading with PrP98–127 induces
mostly IL-4 secretion.
Next, we assayed the sera from DC-immunized wt mice for
the presence of Abs against native PrPc. Consistent with
what had been observed for lymphokine secretion, Ab
responses were essentially seen in wt mice that had been
injected with peptide-loaded DCs. Both PrP158–187 and
PrP98–127 generated similar response patterns with large
variations between individual mice, indicating that tolerance
had not been equally overcome. Differences between the four
vaccination regimens were significant by Kruskal–Wallis test
(P50.018). Dunn two by two indicated that there was no
significant difference between the two groups immunized
with the two respective peptides. Characterization of anti-
PrP Ab subclasses revealed that both IgG1 and IgG2a were
secreted, thereby confirming the involvement of T-cell help
in the anti-PrP response (Fig. 3b). We checked that the
response was really targeted at PrP by testing sera on
recombinant PrP in an ELISA assay (Fig. 3c, d).
DCs must express constitutive PrPc, in addition to
loaded peptides
Next, we asked whether T and B cells cooperating for the
Ab response recognized different antigenic determinants
from the loaded peptides, or whether B cells were directly
activated by the PrPc constitutively expressed on the DC
cell surface. First, we compared responses generated by
peptide-loaded DCs which did or did not express
constitutive PrPc on their surface. Fig. 4(a) shows that
PrP2 DCs were significantly less efficient at eliciting Ab
than PrP+ DCs, irrespective of the loading peptide.
Epitope mapping further confirmed that B cells recognize
antigenic motives of PrPc on the DC surface, absent from
the loading peptide. In addition, sera displayed recurrent
epitope patterns, irrespective of whether they had been
raised with PrP98–127-loaded or PrP158–187-loaded DCs
(Fig. 4b). In all cases, PrP23–52, which has no overlap with
the two loading peptides, was best recognized, followed by
PrP83–112, PrP98–127 and PrP143–172. Of note, PrP158–187 was
not recognized by Abs.
Vaccination with peptide-loaded DCs confers
protection
Having shown that peptide-loaded DCs raised immune
responses to PrP in tolerant wt mice, we attempted to use
DCs as a vaccine to confer protection against scrapie. We
chose PrP98–127 on the basis of several observations,
indicating that this peptide is more Th2-oriented
(Fig. 2b). Ten wt mice receiving a total of seven injections
of PrP98–127-loaded DCs and 12 controls receiving PBS
were infected i.p. with a lethal dose of 139A scrapie, 7 days
after the second DC injection, i.e. 21 days after the
beginning of the protocol. These mice were allowed to
develop scrapie to its terminal phase. In addition, two PBS
controls and four vaccinated mice were culled at 75 days
post-inoculation (p.i.), after five DC injections, to evaluate
the effect of DC vaccination on prion lymphoinvasion.
Fig. 2. Lymphokine secretion by T cells in wt mice immunized with
loaded or unloaded PrP+ DCs. (a) Frequencies of IFN-c-secreting T
cells in response to challenge with the same peptide with which they
were loaded (15 mg ml”1). T cells immunized with unloaded DCs
were challenged in vitro with PrP158–187. Medians (short horizontal
lines) between groups were significantly different by Kruskal–Wallis
test (P,0.001). Dunn’s two by two comparison showed a significant
difference (P,0.01) between DCs loaded with PrP158–187 and DCs
loaded with PrP98–127 or unloaded DCs. (b) Frequencies of IL-4-
secreting T cells probed as described in (a). Medians between
groups were statistically different by Kruskal–Wallis (P,0.001).
Dunn’s two by two comparison showed a significant difference
between PrP158–187-loaded DCs and unloaded DCs (P,0.01) and
between PrP98–127-loaded DCs and unloaded DCs (P,0.05), but
not between the two peptide-loaded groups.
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PrPSc was examined directly in mesenteric lymph nodes by
immunohistochemistry and measured quantitatively with
an anti-PrPSc ELISA in the spleen. PrPSc had accumulated
less in mesenteric lymph nodes of DC-vaccinated mice
compared with controls (Fig. 5a) and quantitative
assessment of PK-resistant PrPSc by ELISA clearly showed
that vaccinated mice had also accumulated significantly less
PrPSc in their spleen at 75 days p.i. (Fig. 5b). In light of
these results, DC vaccination seems to slow down
lymphoinvasion.
We also examined the effect of DC vaccination on mouse
survival. The individual disease courses are shown in
Table 1. Two of the ten DC-vaccinated mice remained
totally free of disease after more than 1 year’s observation.
The eight other mice became sick, with a median
incubation period of 191 days p.i. versus 167 days p.i. in
controls (P,0.0005 by Mann–Whitney test; Fig. 5c).
Neurological symptoms also developed more slowly (59
versus 44.5 days p.i., P,0.005) resulting in an extension of
the median total disease duration to 254 versus 214 days
p.i. (P,0.0005).
Although vaccinated and control mice which suc-
cumbed to the disease displayed typical neurological
signs of 139A scrapie, we looked for the presence of
PrPSc in brains, asking whether the amount of the
pathological protein was reduced in brains of protected
mice. Fig. 5(d) shows the typical three band electro-
phoretic profile of PK-digested PrPSc. All five lanes
including one PBS control sample and four vaccinated
samples, loaded at 3 mg total brain protein, gave a
comparable signal. Thus, at the terminal stage, pro-
tected and control mice contain similar amounts of
pathological protein. No difference was seen between
vaccinated mice #3 and #4, which survived longer and
produced higher MFI values, and vaccinated mice #1
and #2.
Fig. 3. MFI values produced by Abs against native PrPc in wt mice immunized with loaded or unloaded DCs. (a) Compilation of
three independent fluorescence experiments on activated EL4 cells. Sera are shown at a 1 : 20 dilution. Samples were collected
from mice immunized at least two or three times at 15 day intervals with DCs. Short horizontal lines represent the geometric
means. (b) Representative histograms of EL4 cells stained with normal mouse serum (control) or with an immune serum from a
mouse injected twice with PrP98–127-loaded DCs (immune) and revealed with anti-IgG1 or anti-IgG2a Abs. Sera were diluted
at 1 : 20. (c) ELISA against coated recombinant murine PrP. As in (a), the best Ab responses against recombinant PrP,
measured by ELISA, were again obtained with DCs loaded with peptide. ANOVA followed by a Dunn’s two by two test reached
significance between either one of the peptide-loaded groups versus PrP-negative DCs, but not between unloaded PrP+ DCs
and PrP” controls. (d) Assessment of the specificity of the Ab for recombinant PrP. As shown by a cross-ELISA, sera raised by
DC vaccination recognized plastic-bound PrP, but not ovalbumin, while anti-ovalbumin sera recognized only their specific
antigen.
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Fig. 4. Requirement for constitutive PrPc expression on loaded DCs. (a) MFIs of sera from wt mice immunized with
PrP98–127-loaded (m or m) or PrP158–187-loaded (. or .) PrP
” DCs (open) or PrP+ DCs (filled). Sera are shown at a dilution
of 1 : 20. (b) Epitope mapping of polyclonal sera generated with loaded DCs. Sera were assayed by ELISA as described in
Methods. Each serum is representative of two others tested under the same conditions. Peptides are positioned in their
natural order from N- to C-terminus as shown on the x-axis. Black columns are the peptides recognized in common by the two
sets of immune sera.
Table 1. Clinical course in individual DC-vaccinated versus control mice













1 175 235 60 11 164 212 48
2 191 238 47 12 170 214 44
3 191 245 54 13 164 209 45
4 191 249 58 14 164 200 36
5 191 254 63 15 164 215 51
6 191 254 63 16 170 216 46
7 200 255 55 17 170 214 44
8 200 269 69 18 164 208 44
9 .365 .365 No signs 19 164 222 58
10 .365 .365 No signs 20 170 205 35
21 170 222 52
22 170 214 44
Median day 191* 254* 59D 167 214 44.5
*P,0.0005 by Mann–Whitney test between vaccinated and control mice.
DP,0.005 by Mann–Whitney test between vaccinated and control mice.
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We also looked for the presence of PrPSc in the brains and
spleens of the two vaccinated mice that did not develop
clinical scrapie. Western blots were run with an equivalent
of 10 mg protein. Still, PK-digested lanes were totally free
of PrPSc and remained negative even at long exposures
(Fig. 5e).
Protection is correlated with Ab response and not
disorganized germinal centre (GC) micro-
architecture
In order to assess a correlation between survival and Ab
secretion with maximal confidence, we increased the
sensitivity of the EL4 assay, as described in Methods.
Fig. 5. (a) Immunohistochemical detection of PK-resistant PrPSc on mesenteric LN sections of a vaccinated (left) and a control
(right) mouse (40). (b) PK-resistant anti-PrPSc measured by ELISA in spleen lysates of vaccinated (n52) and control (n54)
mice. Data shown are the mean±SEM OD450 values. (c) Onset of disease in vaccinated (#) versus control ($) mice. (d)
Western blot detection of PrPSc in brains of terminally sick mice. The five lanes show PK-digested brain samples: there is one
PBS control and four DC-vaccinated mice with a total disease duration of 235, 238, 245 and 249 days p.i., respectively,
compared with 214 days p.i. for the PBS control. A precipitate extract corresponding to 3 mg brain was loaded in each well;
blots were exposed for 3 min. (e) No PrPSc was detected by Western blot in the brains and spleens of the two DC-vaccinated
survivors (survivor 1 and 2). Infected control is a brain extract of a mouse from the control group which was infected and died
from scrapie; normal brain is from a healthy B6 mouse. A precipitate extract equivalent to 10 mg tissue, digested (+) or not (”)
was loaded in each well and exposure was for 1 min.
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MFI values detected under such conditions ranged from 25
to 300 arbitrary units, at a serum dilution of 1 : 50. Plotting
individual serum values at 45 days p.i. against individual
disease duration gave a positive linear correlation (Fig. 6a),
with an r2 value of 0.7584 and significance of P,0.005.
Most interestingly, the serum MFI values of the two mice
still free of symptoms at 400 days p.i. (therefore not shown
in Fig. 6a) were remarkably high, compared with the MFIs
of the other eight mice in the group (Fig. 6b), again
underlining the importance of Abs in disease protection.
In order to rule out the possibility that multiple injections
of loaded DCs might have disorganized GC micro-
architecture, resulting in disease retardation, we examined
in detail lymph nodes (LNs) from mice after five injections
of 16106 peptide-loaded DCs. Microphotographs of a
typical LN reveal definite PrPSc deposits in the GC area
(Fig. 7a). H&E staining of serial sections confirms the
presence of normally developed GC (Fig. 7b). A GC seen at
higher magnification (Fig. 7c) reveals the typical presence
of tingible body macrophages and of cells in mitosis. A
follicular DC (FDC) with its two pale nuclei and tightly
associated lymphocytes with chromatin-dense nuclei is
shown in Fig. 7d. In view of these data, characteristic of
many other data, it seems unlikely that repeated DC
injections cause GC disorganization resulting in delayed
scrapie evolution.
DISCUSSION
The aim of the present study was to find out whether DCs
loaded with immunogenic, class II-restricted peptides of
PrP can break self tolerance, induce T- and B-cell-
responses in PrP-expressing wt mice and thus be used as
a vaccine against TSEs. DCs have been recognized for a
long time as the most effective inducers of T-cell responses
and have been used in numerous protocols of cancer
immunotherapy. Most groups have focused on the
activation of cytotoxic CD8+ T cells as these can lyse
MHC class I-positive tumour cells. The induction of
cytotoxic and IFN-c-secreting CD8+ T cells through DC
vaccination was achieved in mice and humans by various
techniques (Nair et al., 2000; Nestle et al., 1998; Yu et al.,
2004). More recently, some investigators have developed
DC protocols to generate responses against MHC class II-
restricted tumour peptides. In human patients, Fay et al.
(2006) have observed IFN-c secretion by CD4+ T cells in
response to repeated injections of DCs loaded with
melanoma peptide. Our protocol of immunization was
inspired by that study and others which involve monthly
injections of DCs directed against weakly immunogenic
tumours (Palucka et al., 2006; Wierecky et al., 2006).
Recent mouse studies (Charalambous et al., 2006) suggest
that targeting a xenogeneic tumour antigen to maturing
DCs via DEC-205 receptors is a very effective way to induce
CD4+ immunity to this antigen. Although DCs have also
been shown to stimulate B cells, fewer studies aimed at
generating humoral responses have been reported so far.
Most of these attempts deal with antigens expressed on
infectious agents and are intended to be developed as anti-
infectious vaccines (Boscardin et al., 2006; Gruber et al.,
2007; Lu et al., 2003). Still, there is increasing evidence of in
vivo physiological interactions between DCs and B cells
which allows the generation of Abs. Experiments published
some years ago showed that DCs had an important role in
initiating and regulating Ab synthesis by acquiring and
keeping protein antigens in a non-degraded form long
enough to allow DC migration to secondary lymphoid
organs and deliver antigen to naive, recirculating B cells
(Wykes et al., 1998). A novel non-degradative pathway of
antigen presentation to B cells was also recently described,
involving internalization of antigen-IgG immune com-
plexes by DCs via their inhibitory FccRIIB receptor
(Bergtold et al., 2005). Finally, it was recently shown by
vital microscopy that, after exiting high endothelial venules
and before entering into lymph node follicles, B cells survey
locally concentrated DCs. Direct engagement of the B-cell
receptor on the DC-associated antigen leads to B-cell
activation, migration arrest, antigen acquisition and extra
follicular accumulation (Qi et al., 2006).
Fig. 6. (a) Correlation analysis between dis-
ease survival and MFI values of sera collected
at 45 days p.i. in the eight mice that died from
scrapie. Ab visualization was achieved in two
steps as described in Methods. Sera were
tested at several dilutions (1 : 50 is shown). (b)
Scatter plot of MFI values of the eight DC-
vaccinated mice that progressed toward ter-
minal scrapie compared with the two DC-
vaccinated mice that survived over 400 days
p.i.
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In the present study, the injection of PrP+ DCs into Prnp2/2
mice efficiently induced the generation of T cells producing
cytokines and of B cells secreting Ab directed against cell-
bound native PrPc. This occurred without peptide loading
or addition of free PrP or peptides, suggesting that PrP+
DCs do naturally process MHC class II-restricted peptides
in sufficient amounts to activate CD4+ T cells and display
enough PrPc conformational epitopes for activating B
cells. Presentation to T and B cells was most probably
effected by the injected DCs themselves, as no other cell in
the recipient expressed PrPc. Still, the possibility remains
that recipient DCs engulf or trogocytose elements of
donor DCs and present them in turn to T and B cells, as
already reported in other models of DC immunization
(Herrera et al., 2004).
Injecting PrP+ DCs into wt recipients under the same
conditions was clearly insufficient to either elicit cytokine
release by CD4+ T cells (Fig. 2) or anti-PrPc Abs by B cells
(Fig. 3). PrP+ DCs had to be loaded with PrP98–127 or
PrP158–187 in order to elicit cytokines and Abs. Consistent
with previous studies in Prnp2/2 mice (Gregoire et al.,
2004), loading DCs with PrP158–187 gave a potent T cell
stimulus, and triggered both IFN-c and IL-4. Loading with
PrP98-127 elicited a more discrete response almost exclu-
sively centred on IL-4. Most importantly, immunizing with
PrP158–187- or PrP98–127-loaded DCs resulted in Ab
production which steadily increased with the number of
injections (data not shown). Mice injected with PBS or
PrP2 DCs gave MFIs ranging between 7 and 15 arbitrary
units, which corresponds to background values given by
normal mouse sera. PrP158–187 and PrP98–127 were equally
potent at eliciting Ab responses (Fig. 3a). The fact that
responses were dispersed and globally lower than those of
the Prnp2/2 MFIs in Fig. 1(d) suggests that B- and T-cell
precursors are limiting, due to immune tolerance, and that
the repertoire which escapes tolerance in wt mice is more
difficult to activate. The fact that Abs to cell-surface PrPc
are nevertheless generated in wt mice proves that helper T-
and B-cell repertoires directed against PrPc epitopes are
not totally purged as previously suggested (Gregoire et al.,
2005; Polymenidou et al., 2004).
Lastly, we tested the possibility that peptide-loaded DCs
might be used as vaccines to prevent prion diseases. We
chose PrP98–127 because it elicits a more exclusively Th2-
oriented response, thus avoiding putative Th1 complica-
tions. Iterative injections of PrP98–127-loaded DCs resulted
in a 20% reduction of the attack rate. Two of 10 vaccinated
mice never became sick. At the time of sacrifice (400 days
p.i.) these mice looked healthy and Western blots of
proteins from their brains and spleens showed no traces of
PrPSc (Fig. 5e). The eight vaccinated mice that finally
succumbed to scrapie, had a delayed onset and a slightly
Fig. 7. Photographs of a LN at 75 days p.i.,
i.e. 1 week after the fifth consecutive injection
of loaded DCs. (a) Immunohistochemistry
reveals the presence of PrPSc decorating
GCs (100 magnification). (b) Serial sections
stained with HE showing normally developed
GC (200) (lower left). (c) GC at higher
magnification (400) displays two tingible
body macrophages (arrows) and one cell in
mitosis (circled). (d) A typical FDC with two
chromatin light nuclei and chromatin-dense
tightly associated lymphocytes (oil immersion,
1000).
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slower clinical course. The fact that, at 75 days p.i.,
mesenteric lymph nodes and spleens of DC-vaccinated
mice contain less PrPSc than a similar control organ
suggests that the delayed onset is probably related to a
delayed lymphoinvasion. A correlation was also established
between disease duration and Ab MFI values (Fig. 6a;
correlation coefficient r250.7464 and P-value50.0057),
strongly indicating that Abs to native PrPc are critical to
convey anti-scrapie protection. However, the possibility
that T-cell responses concomitantly elicited by peptide-
loaded DCs may have also contributed to protection
cannot be excluded. This issue is currently under
investigation in our laboratory by adoptive cell transfer
experiments. Given that no correlation was found between
prolonged survival in DC-vaccinated mice and the amount
of PrPSc deposits in the brain (Fig. 5), it can be concluded
that at the terminal stage, prion expansion is the same
whatever the prior course of the disease may have been.
The fact that surviving mice had absolutely no PrPSc in
their spleens and high Ab titres suggests that DC
vaccination can in some cases completely block PrPSc
replication/accumulation in lymphoid organs, rather than
simply hamper neuroinvasion.
We could exclude the possibility that scrapie retardation in
vaccinated mice resulted from a GC architecture made
chaotic by multiple injections of loaded DCs (Brown et al.,
1999; Heikenwalder et al., 2004; Mabbott et al., 2000;
Montrasio et al., 2000). LN sections performed after mice
had received five DC administrations show a normal GC
architecture with abundant PrPSc deposits, a typical
presence of tingible body macrophages, cells in mitosis
and FDCs.
Compared with other protocols of active therapy against
TSE, DC vaccination appears to be among the most
efficient. Active vaccination with recombinant PrP in
complete Freund’s adjuvant was tested by Sigurdsson et al.
(2002). It delayed onset after i.p. infection and extended
survival by 16 days compared with controls. Active
immunization with PrP98–127 or PrP158–187 in the presence
of CpG induced T cells and Ab production but prolonged
mouse survival by only 20 days (Sacquin et al., 2008).
More encouraging results have been obtained by Goni et al.
(2008) following oral immunization with Salmonella
typhimurium encoding one or two copies of mouse Prnp
in their genome. The attack rate was reduced down to zero
in mice immunized six times prior to challenge and
selected for high IgA production. The advantage of using
DCs as a vaccine support was also demonstrated in a recent
study performed by a member of our group (Rosset et al.,
2009). There, the main principle relied on the transduction
of DCs from wt mice with a recombinant adenovirus
coding for human PrP (hPrP), followed by administration
into wt mice subsequently infected with a scrapie agent.
Clinical disease was significantly delayed in the groups
which received DCs expressing mouse PrPc and transduced
with adenovirus (Ad) encoding hPrPc or transduced with a
control Ad. However, the best protection was obtained
after vaccination with transgenic DCs expressing hPrP and
transduced by a control Ad.
In the study by Rosset et al. (2009), both PrP-specific
cytotoxic T cells and Ab responses were analysed and
circulating Abs against native mouse PrPc were signific-
antly increased; however, the exact immune mechanisms
involved were not precisely identified. Interestingly, Abs
against native mouse PrP were far less efficiently generated
in mice directly immunized with recombinant adeno-
viruses encoding hPrP, thereby underlining the advantage
of targeting antigen to DCs.
The present study, in contrast with that of Rosset et al.
(2009), used exclusively non-transduced DCs administered
immediately after differentiation/maturation and loaded
with well-defined peptides. Special attention was given to
understanding the role of each immunogenic constituent,
i.e. the PrPc expressed on DCs and the loaded peptides.
Results show that in order to break tolerance in PrP+ mice,
DCs must not only be loaded with peptide but also express
constitutive PrPc (Fig. 4a). This result suggests that T and
B cells recognize determinants of different origin on DCs. T
cells bind to class II-restricted epitopes which result from
the processing of the loading peptides, whereas B cells are
probably activated by conformational PrPc epitopes
displayed at the surface of the DC. Because we have
reported in a previous study that PrPc is involved in the
formation of the T/DC synapse and its absence or its
masking by Ab hampers T/DC interactions (Ballerini et al.,
2006), we cannot totally rule out the possibility that the
reduced immunogenicity of PrP2 DCs may also result
from a weaker activation of helper T cells. Still, an
additional proof that B cells are activated by determinants
independent of the loading peptides was provided by
epitope mapping of Abs. The pattern of peptide recog-
nition was remarkably recurrent among sera, regardless of
whether DCs had been loaded with PrP98–127 or PrP158–187.
Interestingly, dominantly recognized epitopes were con-
centrated in the flexible N-terminal domain of the protein
which is likely to be the most exposed (Donne et al., 1997).
Whereas PrP158–187 is a dominantly recognized T-cell
peptide, there was no Ab binding to it, confirming the
independence between Ab fine specificities and T-cell
epitopes.
From the perspective of applying DC vaccination to human
patients, DCs cultured in vitro can be used with no further
manipulation and by simple loading with synthetic, pure
and well-defined immunogenic peptides. Virally trans-
duced DCs also afford good protection and have the
advantage of not requiring the identification of peptides
restricted to a given MHC context. On the other hand, they
involve a supplementary step of recombinant adenovirus
production and transduction and may therefore be less safe
or easy to use than DCs expanded in vitro from a patient
and simply loaded with synthetic peptides before reinjec-
tion. In any case, introducing DC vaccine protocols in the
field of neurodegenerative diseases opens promising
Dendritic cell vaccination against prions
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perspectives. The ongoing work produced in cancer
therapy will be most useful for developing safe and efficient
DC vaccines against TSE and, more generally, against
neurodegenerative conditions.
METHODS
Mice. Prnp2/2 mice were from the original 1296B6 Zurich nucleus
(Bueler et al., 1992) (with kind permission from C. Weissmann,
Scripps Institute, Florida). The null mutation was subsequently back-
crossed in our facility onto B6 mice. Prnp2/2 mice used throughout
this study were homozygous offspring derived from back-cross 12.
B6 wt mice are fully histocompatible with Prnp2/2 mice, as assessed
by reciprocal skin grafting. All mice were raised and maintained
under strictly monitored specific-pathogen-free conditions.
Experimentation was conducted in accordance with the French
legislation and European Community recommendations.
Peptides. PrP97–128 and PrP158–187 are two immunogenic peptides
recognized by CD4+ T cells in a class II, I-Ab context. They were
previously identified out of a bank of 13 peptides, mostly 30-mers,
with a 15 aa overlap on each side (Gregoire et al., 2004). The bank was
synthesized by NeoMPS (Strasbourg, France) with a minimum of
80% purity. Both PrP98–127 and PrP158–187 are soluble in water
without addition of DMSO, at a 106 concentration of 150 mg ml21
and are LPS-free.
DC generation. BM-derived DCs (BMDCs) were differentiated from
femur and tibia BM of 8- to 10-week-old wt or Prnp2/2 female mice
(Weigel et al., 2002). Cells were cultured in RPMI 1640 (Gibco
Invitrogen) supplemented with 10% FCS, penicillin/streptomycin
(1000 IU ml21/10 mg ml21), 2 mM glutamine and 0.05 mM 2-
mercaptoethanol. Granulocyte-macrophage colony-stimulating factor
(PeproTech) was added at 200 U ml21 from the onset and renewed at
days 3 and 6. On day 7, DCs were recovered, adjusted to 16106 cells
ml21 and matured overnight with LPS at 2 mg ml21 (Sigma). They
were collected the following day and pulsed for 4 h, at a
concentration of 26106 cells ml21, with 10 mM peptide PrP98–127
or PrP158–187 and then washed three times in PBS. All batches of DCs
were monitored, by flow cytometry, for high CD11c, MHC class II,
CD80 and CD86 expression (data not shown), using a FACSCalibur
and CellQuest Pro software (Becton Dickinson).
DC injections. DCs were prepared as described above and injected
i.p. in PBS at a concentration of 16106 per mouse. Mice periodically
treated against scrapie received a total of seven DC injections; the first
three were at 15 day intervals and the remaining four were at monthly
intervals. Seven days after the second DC injection (d21), mice were
infected i.p. with a 139A inoculum of 26104 LD50.
ELISPOT assay. IFN-c- and IL-4-producing T cells were enumerated
by ELISPOT as described previously (Ballerini et al., 2006). T cells
(26105 per well) enriched by negative magnetic selection and spleen
DCs (1.56104 per well) positively selected with a CD11c magnetic kit
(Miltenyi Biotec) were plated together onto nitrocellulose-based
microplates (Millipore). Abs against IFN-c were clone R4-6A2 for
capture and XMG1.2 for revelation (PharMingen). For IL-4, we used
the Ab from the IL-4 ELISPOT kit (R&D). PrP98–127 or PrP158–187
were added at 15, 1.5, 0.15 and 0 mg ml21 and plates were incubated
for 24 h for IFN-c or 48 h for IL-4. Spots were counted using an
automatic ELISPOT plate counter (AID). Results are expressed as the
average number of spots per 16106 T cells. Because unloaded DCs
are sufficient to elicit non-specific stimulation of T cells from DC-
vaccinated mice (Palucka et al., 2005), results are presented as: (the
number of spots generated in the presence of DCs+
peptide)2(background number of spots generated with unloaded
DCs).
Solid phase ELISA. ELISA against a bank of plastic-immobilized
peptides was performed as described previously (Gregoire et al.,
2005). Sera were distributed as duplicates at a 1 : 50 dilution and left
for 2 h at room temperature on antigen-coated polypropylene
microtitre plates (Maxisorb). Bound Ab was revealed with goat
anti-total mouse Ig or goat anti-mouse IgM, IgG1 or IgG2a, coupled
to peroxidase (Roche). The chromogenic reaction was generated in
the presence of H2O2 with phenylenediamine in 0.05 M citrate buffer
(Sigma) and was stopped with 25 ml 2 N sulfuric acid. SAF84, a
monoclonal Ab directed against mouse PrP, served as a positive
standard.
Indirect immunofluorescence on EL4 cells for anti-native PrPc
Abs. Ab binding to cell-surface native PrPc was detected by
immunofluorescence on the EL4 T cell line as described previously
(Gregoire et al., 2004). Since EL4 cells express relatively low levels of
membrane PrPc under spontaneous conditions, they were stably
transfected with the Prnp gene and were activated before each test in
order to optimize the sensitivity of Ab detection. EL4 cells collected
24 h after their last passage, were incubated overnight with anti-CD3
Ab (clone 2C11), plated at 10 mg ml21. Dilutions of sera at 1 : 20,
1 : 50 and 1 : 100 were incubated for 20 min with 16105 activated EL4
cells. Bound Ab was revealed with the following secondary antibodies:
either mark1, a rat anti-mouse k-chain monoclonal Ab coupled to PE
(Cormont et al., 1986), or polyclonal rat anti-mouse IgG1 or anti-
IgG2a coupled to FITC or PE (Becton Dickinson). Every assay
includes normal B6 mouse sera as background controls and anti-PrPc
SAF-84 monoclonal Ab as the upper limit. Cell-surface fluorescence is
expressed as the geometric MFI, measured by flow cytometry on a
FacsCalibur with CellQuest-Pro software. In the assays aimed at
correlating MFIs with survival (specified in Results and in legend to
Fig. 6), the MFI signal was reinforced by a two step visualization:
firstly with a biotinylated rat anti-mouse IgG and secondly with
streptavidin–allophycocyanin (all from Becton Dickinson).
Scrapie inoculation. The 139A strain of scrapie has been serially
passaged by intracerebral injection into B6 mice. An infectious stock
(10% w/v in PBS) was prepared out of a pool of brains from
terminally ill mice. Mice were infected i.p. with 0.1 ml homogenate at
0.5% representing 26104 LD50 units, 7 days after the second DC
immunization, therefore 21 days after the start of the vaccination
process. They were scored as clinically sick after three consecutive
observations of reduced activity in the cage and poor gait control
when crossing a set of regularly spaced bars, as described previously
(Aucouturier et al., 2001).
Anti-PrPSc ELISA. The ELISA was performed with the TeSeE Sheep/
Goat ELISA kit (Bio-Rad) according to the manufacturer’s recom-
mendations, with minor modifications. Spleens were resuspended in
10% (w/v) lysis buffer. ELISA was performed on 100 ml spleen lysate.
Western blots. Brain or spleen samples were prepared at 10% (w/v)
in PBS plus protease inhibitors (Complete, Roche Diagnostic).
Homogenization was performed with the Fast Prep method applied
for 40 s. One aliquot was digested at 37 uC for 15 min with proteinase
K (PK) (Roche, Meylan, France) at 10 mg ml21, the other was left
intact. Aliquots equivalent to 3 mg or 10 mg of original tissue, as
specified in the legend to Fig. 5d, e and Results, were separated on
12% SDS-PAGE. Samples were subsequently transferred to nitro-
cellulose membranes and revealed with mAb SAF-84 at 1 : 5000,
followed by incubation with a goat anti-mouse Ig coupled to
peroxidase and chemiluminescent substrate. Signal was captured with
a Fujifilm LAS3000 camera for 1 min. Longer exposures (not shown)
V. Bachy and others
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were done to demonstrate complete PK-digestion of PrPc and the
absence of any trace of PrPSc in protected mice
Histology. GC micro-architecture was analysed on fixed 5 mm serial
sections, stained with haematoxylin and eosin, and examined at
various magnifications. Photographs were taken with an Olympus
BX51 microscope equipped with an Olympus DP50 camera.
PrPSc was detected by immunohistochemistry on fixed 5 mm
contiguous sections as described previously (Levavasseur et al.,
2007). Sections were treated with 98% formic acid, heated for 10 min
at 121 uC in 10 mM citrate buffer pH 6.1 and digested with 10 mg
ml21 PK. PrP resistant to proteinase K digestion (PrPres) was
revealed for 60 min with mAb SAF84, followed by 30 min with the
peroxidase-conjugated EnVision reagent (K4000, Dako). Slides were
counterstained with Mayer’s haematoxylin.
Statistics. Analyses were performed with GraphPad software and
values were considered significantly different for P,0.05. When more
than two groups of data were compared, the Kruskal–Wallis
multivariate analysis was used, followed by a Dunn’s post-test. A
non-parametric Mann–Whitney test was used for comparing two sets
of data. Correlation coefficient r2 and statistical significance was
established by linear regression.
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